XML 30 R7.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:      
Net loss $ (146,412) $ (162,857) $ (146,398)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation of property and equipment 18,439 12,537 12,758
Amortization and impairment of intangible assets 3,732 78,312 11,637
Amortization of operating lease right-of-use assets 6,650 6,149 6,499
Stock-based compensation 55,792 67,581 64,183
Fair value (gain) loss on contingent consideration and investments 4,529 (64,727) (8,018)
Other (3,331) (19,708) 2,237
Changes in operating assets and liabilities:      
Research fees and grants receivable (55,623) (75,119) (45,933)
Income taxes (payable) receivable (29,843) 6,651 30,464
Accounts payable and accrued liabilities 3,457 10,635 (15,104)
Deferred revenue (2,195) (7,931) (13,976)
Deferred grant income (3,638) 33,967 39,521
Other assets 17,148 5,954 18,253
Net cash used in operating activities (131,295) (108,556) (43,877)
Cash flows from investing activities:      
Purchases of property and equipment (42,772) (78,396) (76,947)
Purchase of marketable securities (436,044) (765,086) (1,021,510)
Proceeds from marketable securities 506,072 937,882 910,937
Receipt of grant funding 21,343 35,708 25,311
Distribution from equity accounted investees 30,113 0 0
Investment in and loans to equity accounted investees (7,137) (19,626) (13,690)
Proceeds from repayment of loan from joint venture partner 33,268 0 0
Long-term investments and other assets (17,093) 10,927 (45,209)
Net cash provided by (used in) investing activities 87,750 121,409 (221,108)
Cash flows from financing activities:      
Payment of liability for in-licensing agreement and other (15,649) (729) (1,234)
Proceeds from long-term liabilities and other 29,731 13,498 11,590
Net cash provided by financing activities 14,082 12,769 10,356
Effect of exchange rate changes on cash and cash equivalents 1,097 (2,617) 589
Increase (decrease) in cash and cash equivalents (28,366) 23,005 (254,040)
Cash and cash equivalents and restricted cash, beginning of period 183,615 160,610 414,650
Cash and cash equivalents and restricted cash, end of period 155,249 183,615 160,610
Restricted cash included in other assets 1,736 2,290 2,290
Total cash, cash equivalents, and restricted cash shown on the balance sheet 153,513 181,325 158,320
Supplemental disclosure of non-cash investing and financing activities      
Property and equipment in accounts payable 1,995 12,767 13,625
Right-of-use assets obtained in exchange for operating lease obligation $ 76,118 $ 1,898 $ 1,199